IND226 also presented at the World Conference on Lung Cancer

Planned System Maintenance

Starting Sunday, November 18th, 2018 beginning at 7:00 AM EST, and ending on Sunday, November 18th, 2018 at 9:00 AM EST. During this time there will be no access to the system including patient enrollments.
Please share this notification to the personnel who will be affected by this within your organization.
Maintenance Start: Sunday, November 18th, 2018, 7:00 AM EST.
Maintenance End: Sunday, November 18th, 2018, 9:00 AM EST.
We are sorry for any inconvenience this may cause.

Thursday, December 15, 2016
Dr. Rosalyn Juergens, the study chair of IND.226, gave an oral presentation of the experience to date on IND.226, A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens at the 17th Annual World Conference on Lung Cancer in Vienna, Austria. She presented data of 24 patients with advanced non-small-cell lung cancer which found that, in this PD-1 unselected patient population, durvalumab 15mg/kg q3w and tremelimumab 1mg/kg (multiple doses q6w) or 3mg/kg (3 doses q6w) can be safely combined with full doses of platinum-doublet chemotherapy. Additional studies with this combination are being planned, including BR.34.

You can view the complete abstract presented by Dr. Juergens using this link


Dr. Rosalyn Juergens